Trial Profile
Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dornase alfa (Primary)
- Indications Cystic fibrosis; Rhinosinusitis
- Focus Therapeutic Use
- 10 Dec 2014 New trial record